Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -206.32% is 525% below its 3-year average of -33.03%, near the low end of its 3-year range (-206.32%–0.00%).
288.22% below its 12-month average of -53.14%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -64.86%.
RETURN ON ASSETS (ROA)
-206.32%
RETURN ON ASSETS (ROA) AVG TTM
-53.14%
RETURN ON ASSETS (ROA) AVG 3Y
-33.03%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-288.22%
CURRENT VS 3Y AVG
-524.69%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-539.45%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.07M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
N/A
Market Cap
$7.04M
Return on Assets (ROA)
-95.26%
TTM Avg
-176.86%
3Y Avg
-120.19%
5Y Avg
-105.02%
Market Cap
$7.12M
Return on Assets (ROA)
-457.62%
TTM Avg
-117.02%
3Y Avg
-190.78%
5Y Avg
-182.53%
Market Cap
$7.15M
Return on Assets (ROA)
-151.57%
TTM Avg
-141.88%
3Y Avg
-132.44%
5Y Avg
-101.65%
Market Cap
$7.19M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$7.19M
Return on Assets (ROA)
-1082.20%
TTM Avg
-652.69%
3Y Avg
-445.69%
5Y Avg
-363.52%
Market Cap
$6.88M
Return on Assets (ROA)
-72.69%
TTM Avg
-49.83%
3Y Avg
-64.20%
5Y Avg
-63.36%
Market Cap
$7.31M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$6.74M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.07M | -206.32% | -53.14% | -33.03% | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.04M | -95.26% | -176.86% | -120.19% | -105.02% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | -457.62% | -117.02% | -190.78% | -182.53% |
| Longeveron Inc. (LGVN)vs › | $7.15M | -151.57% | -141.88% | -132.44% | -101.65% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.19M | -283.63% | -124.17% | -74.25% | -35.74% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.19M | -1082.20% | -652.69% | -445.69% | -363.52% |
| Exicure, Inc. (XCUR)vs › | $6.88M | -72.69% | -49.83% | -64.20% | -63.36% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -414.54% | -226.50% | -135.75% | -126.75% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | -71.23% | -61.08% | -51.04% | -61.11% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | -74.58% | -69.72% | -51.64% | -52.44% |
ROA
-206.3%
ROE
-218.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -36.49% |
| 2024-12-31 | -69.80% |
| 2023-12-31 | -25.82% |
| 2022-12-31 | 0.00% |
